These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 19178029)
21. Carvedilol: use in chronic heart failure. Doughty RN; White HD Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454 [TBL] [Abstract][Full Text] [Related]
22. [A fairer comparison between carvedilol and metoprolol is still to be done]. Johnsson G; Aberg J Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018 [No Abstract] [Full Text] [Related]
23. Carvedilol prevents myocardial fibrosis in hamsters. Nanjo S; Yamazaki J; Yoshikawa K; Ishii T; Togane Y Int Heart J; 2006 Jul; 47(4):607-16. PubMed ID: 16960415 [TBL] [Abstract][Full Text] [Related]
24. Carvedilol therapy in pediatric patients with dilated cardiomyopathy. Askari H; Semizel E; Bostan OM; Cil E Turk J Pediatr; 2009; 51(1):22-7. PubMed ID: 19378887 [TBL] [Abstract][Full Text] [Related]
25. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA; Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806 [TBL] [Abstract][Full Text] [Related]
26. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. El-Shitany NA; Tolba OA; El-Shanshory MR; El-Hawary EE J Card Fail; 2012 Aug; 18(8):607-13. PubMed ID: 22858075 [TBL] [Abstract][Full Text] [Related]
27. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ]. Torp-Pedersen CT; Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171 [No Abstract] [Full Text] [Related]
28. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. Rusconi P; Gómez-Marín O; Rossique-González M; Redha E; Marín JR; Lon-Young M; Wolff GS J Heart Lung Transplant; 2004 Jul; 23(7):832-8. PubMed ID: 15261177 [TBL] [Abstract][Full Text] [Related]
29. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function. Oliveira PJ; Rolo AP; Sardão VA; Monteiro P; Gonçalves L; Providência LA; Palmeira CM; Moreno AJ Rev Port Cardiol; 2004 Oct; 23(10):1291-8. PubMed ID: 15641294 [TBL] [Abstract][Full Text] [Related]
30. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ; Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773 [TBL] [Abstract][Full Text] [Related]
31. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941 [TBL] [Abstract][Full Text] [Related]
32. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol]. Swedberg K Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169 [No Abstract] [Full Text] [Related]
33. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. DasGupta P; Broadhurst P; Lahiri A J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973 [TBL] [Abstract][Full Text] [Related]
34. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis. Xu L; Long Y; Tang X; Zhang N Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905 [TBL] [Abstract][Full Text] [Related]
35. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708 [TBL] [Abstract][Full Text] [Related]
36. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Bell DS; Lukas MA; Holdbrook FK; Fowler MB Curr Med Res Opin; 2006 Feb; 22(2):287-96. PubMed ID: 16466600 [TBL] [Abstract][Full Text] [Related]
37. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705 [TBL] [Abstract][Full Text] [Related]
38. [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. Oleĭnikov VE; Matrosova IB; Eliseeva IV; Tomashevskaia IuA; Gusakovskaia LI Kardiologiia; 2009; 49(11):27-32. PubMed ID: 20001979 [TBL] [Abstract][Full Text] [Related]
39. Cardioprotective activity of standardized extract of Ficus racemosa stem bark against doxorubicin-induced toxicity. Ahmed F; Urooj A Pharm Biol; 2012 Apr; 50(4):468-73. PubMed ID: 22136326 [TBL] [Abstract][Full Text] [Related]
40. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B; Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]